BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9666879)

  • 21. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
    Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
    J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P; Hosking D; Thompson D; Cizza G; Wasnich RD; McClung M; Yates AJ; Bjarnason NH; Christiansen C
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
    HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.
    Guo W; Li F; Zhu C; Wang B; Wang K; Dai C; Jia H; Wei H; He Q; Cui J; Yuan M; Tang S; Liu W; Zhu T; Gao Z; Zheng F; Ma Z; Qu H; Zhu M
    J Int Med Res; 2018 Jan; 46(1):492-503. PubMed ID: 28851260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing's syndrome.
    Luisetto G; Zangari M; Camozzi V; Boscaro M; Sonino N; Fallo F
    Osteoporos Int; 2001; 12(11):956-60. PubMed ID: 11804023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.